These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 1382848

  • 1. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
    Bystryn JC, Henn M, Li J, Shroba S.
    Cancer Res; 1992 Nov 01; 52(21):5948-53. PubMed ID: 1382848
    [Abstract] [Full Text] [Related]

  • 2. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
    Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn JC.
    Cancer Res; 1991 Jul 15; 51(14):3643-7. PubMed ID: 2065322
    [Abstract] [Full Text] [Related]

  • 3. Identification of immunogenic B16 melanoma-associated antigens.
    Johnston D, Schachne JP, Bystryn JC.
    J Biol Response Mod; 1987 Apr 15; 6(2):108-20. PubMed ID: 3585408
    [Abstract] [Full Text] [Related]

  • 4. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
    Bystryn JC, Jacobsen S, Harris M, Roses D, Speyer J, Levin M.
    J Biol Response Mod; 1986 Jun 15; 5(3):211-24. PubMed ID: 3723138
    [Abstract] [Full Text] [Related]

  • 5. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells.
    Savage HE, Rossen RD, Hersh EM, Freedman RS, Bowen JM, Plager C.
    Cancer Res; 1986 Apr 15; 46(4 Pt 2):2127-33. PubMed ID: 3948184
    [Abstract] [Full Text] [Related]

  • 6. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
    Berthier-Vergnes O, Portoukalian J, Lefthériotis E, Doré JF.
    Cancer Res; 1994 May 01; 54(9):2433-9. PubMed ID: 8162593
    [Abstract] [Full Text] [Related]

  • 7. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
    Hoon DS, Yuzuki D, Hayashida M, Morton DL.
    J Immunol; 1995 Jan 15; 154(2):730-7. PubMed ID: 7814879
    [Abstract] [Full Text] [Related]

  • 8. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
    Takeyama H, Watanabe T, Livingston PO.
    Gan To Kagaku Ryoho; 1983 Jul 15; 10(7):1624-33. PubMed ID: 6870307
    [Abstract] [Full Text] [Related]

  • 9. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo.
    Applebaum J, Reynolds S, Knispel J, Oratz R, Shapiro R, Bystryn JC.
    J Natl Cancer Inst; 1998 Jan 21; 90(2):146-9. PubMed ID: 9450575
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunophenotype of human melanoma cells in different metastases.
    Bystryn JC, Bernstein P, Liu P, Valentine F.
    Cancer Res; 1985 Nov 21; 45(11 Pt 2):5603-7. PubMed ID: 2413993
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
    Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA.
    J Immunother (1991); 1991 Jun 21; 10(3):153-64. PubMed ID: 1868040
    [Abstract] [Full Text] [Related]

  • 14. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.
    Brown JP, Nishiyama K, Hellström I, Hellström KE.
    J Immunol; 1981 Aug 21; 127(2):539-46. PubMed ID: 6166674
    [Abstract] [Full Text] [Related]

  • 15. Immunofluorescent detection of common melanoma membrane antigens by sera of melanoma patients immunized against autologous or allogeneic cultured melanoma cells.
    Leong SP, Sutherland CM, Krementz ET.
    Cancer Res; 1977 Nov 21; 37(11):4035-42. PubMed ID: 332343
    [No Abstract] [Full Text] [Related]

  • 16. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE.
    Oncol Rep; 2002 Nov 21; 9(2):267-76. PubMed ID: 11836591
    [Abstract] [Full Text] [Related]

  • 17. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC, Abrams JT, Zhang SY, Galili U.
    Cancer Res; 1999 Jul 15; 59(14):3417-23. PubMed ID: 10416604
    [Abstract] [Full Text] [Related]

  • 18. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
    Slingluff CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK.
    Clin Cancer Res; 2007 Nov 01; 13(21):6386-95. PubMed ID: 17975151
    [Abstract] [Full Text] [Related]

  • 19. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
    Taramelli D, Fossati G, Mazzocchi A, Delia D, Ferrone S, Parmiani G.
    Cancer Res; 1986 Jan 01; 46(1):433-9. PubMed ID: 3079589
    [Abstract] [Full Text] [Related]

  • 20. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ, Parkinson DR, Marincola F.
    J Immunother; 1998 Jan 01; 21(1):1-16. PubMed ID: 9456431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.